Progress in cyclin-dependent kinase 1 (CDK 1) in the treatment of liver cancer

Chenyu Gu

doi:10.47297/wspbdsWSP2752-630531.20250501

PDF
Export
Share
Collection
Album

Progress in cyclin-dependent kinase 1 (CDK 1) in the treatment of liver cancer

Volume 5, Issue 1

Views: 0 Downloads: 0

Progress in cyclin-dependent kinase 1 (CDK 1) in the treatment of liver cancer
Progress in cyclin-dependent kinase 1 (CDK 1) in the treatment of liver cancer
China Pharmaceutical University, Nanjing, Jiangsu, 211198, China
Vol. 5, Issue 1, Pages: 139-142(2025)
Published：19 March 2025
DOI：10.47297/wspbdsWSP2752-630531.20250501
Accepted：

Scan QR Code

Gu Chenyu.Progress in cyclin-dependent kinase 1 (CDK 1) in the treatment of liver cancer[J].Biomedical Data Science,2025,05(01):139-142.
DOI：

Gu Chenyu.Progress in cyclin-dependent kinase 1 (CDK 1) in the treatment of liver cancer[J].Biomedical Data Science,2025,05(01):139-142. DOI： 10.47297/wspbdsWSP2752-630531.20250501.

摘要

Abstract

Primary liver cancer is the most widespread and most dangerous cancer in the world. However

in the last decade

the survival rate of patients with liver cancer has not increased. Most directions of liver cancer treatment contain the mechanism of CDK 1

and Cyclin-dependent kinase 1 (CDK 1) is a key enzyme in the regulation of cell cycle progression

especially plays a central role in the initiation and regulation of mitosis (M phase). It binds to cyclin (cyclins) and controls key stages of the cell cycle

including the G2 / M phase. One of the hallmarks of cancer cells is the deregulation of the cell cycle

leading to excessive cell proliferation. At home and abroad for CDK 1 in cancer treatment has made great progress

if the use of CDK 1 in the cell cycle of design drugs to stop the abnormal proliferation of cancer cells

can achieve true treatment in cancer treatment

this paper mainly set the domestic and foreign for CDK 1 in the latest research progress of various cancer treatment

detailed elaboration and summary.

关键词

Keywords

references

Deng Yan , Duan Yong . Progress in the pathogenesis and drug therapy of primary liver cancer [J ] . Hebei Medical Science Center , 2024 , 30 ( 2 ): 345 - 348 .

Qiao Xiansen , Yuan Qing , Chen Yinghui , et al . Effect of dodosocidin on modulating CDK 1 / CCNB 1 / PLK 1 signaling on the malignant biological behavior of HCC cells [J ] . Hebei Medicine , 2024 , 46 ( 23 ): 3540 - 3545 .

Marcos M , Mariano B . Cell cycle, CDKs and cancer: a changing paradigm .[J ] . Nature reviews. Cancer , 2009 , 9 ( 3 ): 153 - 66 .

Zhu Wenwen , Xiao Geqiong . Clinical significance of CDK 1 and CCNB 1 expression levels in hepatocellular carcinoma [J ] . Health Research , 2023 , 43 ( 1 ): 70 - 73,79 .

Yang Ying , Zhang Qimin , Guo Yufan , et al . Effects and action mechanism of CDK 1 gene on the proliferation and migration of HepG 2 and Huh 7 in HCC cells [J ] . Modern Medical Oncology , 2024 , 32 ( 16 ): 2990 - 2998 .

Liu Zitao . PSMD12 Regulating the stability of CDK 1 through deubiquitination promotes the progression of HCC [D ] . And Nanchang University , 2024 .

Ye Kaili , Zheng Wen , Ye Hfa , et al . CDK 1 participates in the development of hepatocellular carcinoma and its value of inhibitor application [J ] . Clinical Pharmacology and Therapeutics of China , 2021 , 26 ( 9 ): 1086 - 1094 .

Zhao Qingzhi . Identification of the CDK 1 acetylation modification site and its biological function [D ] . And Jilin University , 2023 .

Hui Ying , Zeng Hao . SFN gene induced G2 / M phase arrest in HepG 2 cells and its effect on the protein expression of CDK 1 and CCNB 1 [C ] / / Nanjing Rehabilitation Medical Association. Proceedings of the second National Academic Exchange Conference on Rehabilitation and Clinical Pharmacy (I). Laboratory Department of Guigang People's Hospital ;, 2022 : 6 .

Xu Lizhen , Zhu regenerative , Zhou Pengfei , et al . Study of the Eg 5 small molecule inhibitor SB-743921 inhibiting malignant proliferation of castration-resistant prostate cancer cells through the c-Myc / SP 1 / CDK 1 pathway [J ] . Zhejiang Medical , 2023 , 45 ( 15 ): 1609 - 1614,1625 .

Chen Yating . Antitumor effects of natives or natives combined with CDK 1 inhibitors [D ] . Guangzhou University of Traditional Chinese Medicine , 2013 .

Cui Juan . The synergistic killing effect of Utaine combined with CDK 1 inhibitor [D ] . Guangzhou University of Traditional Chinese Medicine , 2011 .

Jorrit E , Richard K . An overview of Cdk1-controlled targets and processes [J ] . Cell Division , 2010 , 5 ( 1 ): 11 .

Chen R. , et al . ( 2012 ). " The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells ." Leukemia , 26 ( 12 ), 2554 - 2557 .

Parry D. , et al . ( 2010 ). " Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor ." Molecular Cancer Therapeutics , 9 ( 8 ), 2344 - 2353 .

Sánchez-Martínez C , Gelbert M L , Lallena J M , et al . Cyclin dependent kinase (CDK) inhibitors as anticancer drugs [J ] . Bioorganic & Medicinal Chemistry Letters , 2015 , 25 ( 17 ): 3420 - 3435 .

Hydbring P. , & Malumbres M . ( 2022 ). A Compendium of Cyclin-Dependent Kinase (CDK) Inhibitors in Oncology . Annual Review of Cancer Biology , 6 , 291 - 311 .

Lu Z , Han J , Ji Y , et al . Computational design of CDK1 inhibitors with enhanced target affinity and drug-likeness using deep-learning framework [J ] . Heliyon , 2024 , 10 ( 22 ): e40345 - e40345 .

Yan Ming , Daystar , Cheng Shi , et al . Significance of cyclin-dependent kinase 1 expression in human colorectal cancer tissues [J ] . Chinese Journal of Clinicians , 2021 , 49 ( 9 ): 1080 - 1082 .

Lim S. , Kaldis P. , & Kalousi A . ( 2020 ). CDK1 as a therapeutic target for cancers . Current Pharmaceutical Design , 26 ( 9 ), 1015 - 1022 .

Yang Kai Wei , Tang Kai , Liao Xia , et al . Based on the bioinformatics study of the expression and clinical significance of CDK 1 in ACC [J ] . Theory and Practice of Medicine , 2024 , 37 ( 16 ): 2701 - 2705,2727 .

Forward , Han Yuchao , Li Shan . Study on the expression of CDK 1 and IL-33 and their malignant biological behavior in colorectal cancer tissues [J ] . Journal of Practical Cancer , 2023 , 38 ( 7 ): 1089-1092 + 1096 .

Uzma A , K A W , C N T , et al . The history and future of targeting cyclin-dependent kinases in cancer therapy . [J ] . Nature reviews. Drug discovery , 2015 , 14 ( 2 ): 130 - 46 .

Alert me when the article has been cited

Submit

The Role of Ras Gene in Cancer and Progress in Antibody Research

Related Author

Guoliang Ma Puyang MedicaI College

Related Institution

Puyang MedicaI College

⁰